Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge

Area of Science:

• Biotechnology
• Nanomedicine
• RNA Therapeutics

Background:

• Functional RNA molecules like aptamers and siRNAs offer versatile structures for nanostructure assembly.
• B-cell activating factor receptor (BAFF-R) is overexpressed on B-cell malignancies, presenting a therapeutic target.

Purpose of the Study:

• To develop novel, cell-type specific, internalizing aptamer-siRNA delivery systems for B-cell lymphoma therapy.
• To utilize BAFF-R targeted nanoparticles for delivering STAT3 siRNAs to malignant B-cells.

Main Methods:

• Conjugation of aptamers and Dicer substrate siRNAs (DsiRNAs) via a "sticky bridge" to create aptamer-siRNA nanoparticles.
• Targeting BAFF-R on B-cell malignancies for nanoparticle binding and internalization.
• Delivery of STAT3 siRNAs to the cytoplasm for gene silencing.

Main Results:

• Successful development of BAFF-R aptamer-siRNA nanoparticles for targeted delivery.
• Demonstrated robust gene silencing of STAT3 mRNAs in various B-cell lines.
• Confirmed that the nanoparticles do not induce cell proliferation or apoptosis.

Conclusions:

• Aptamer-mediated delivery systems offer a promising tool for B-cell lymphoma therapy.
• Targeted delivery of siRNAs via BAFF-R aptamers enables effective gene silencing.
• These nanostructures represent a potential therapeutic modality for various diseases.